Browse every story filed under this topic, curated from trusted publishers around the world.
Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
Avalyn Pharma has overshot its expectations with a $300 million IPO that the biotech will use to fund late-stage studies of its inhaled versions of approved respiratory drugs.
Read full story →
STAT+: A patent win for Pfizer and BridgeBio
A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The …
Eli Lilly signs $2.3b AI biotech deal with Profluent
Lilly has signed at least 15 AI deals in the past five years, boosting its AI drug discovery efforts.
Milestone for CRISPR: First-of-Its-Kind Gene Editing Treatment Successfully Passes Clinical Trial
A biotech company is looking to get approval next after their recent discovery.
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
Seaport and Hemab target $180m IPOs as biotech listings accumulate
Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.
Ligand snaps up fellow biotech royalty aggregator Xoma for $739M
After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out …
STAT+: Astellas retries XLMTM gene therapy after deaths
Veradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech news
UK biotech could be bound for recovery, BIA report reveals
With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British …
STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for …
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Avalyn Pharma is hoping to rake in around $181.8 million from an IPO, which the biotech will use to take …
A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
STAT+: Sanofi research priorities in flux as new CEO logs in
A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout
STAT+: Can Erasca be biotech’s next big thing? We’ll see
Can Erasca be biotech's next big thing?
STAT+: At AACR, talk of Chinese biotech, oncology’s comms issue, and more
At AACR, there was talk of Chinese biotech's place in cancer research, oncology’s comms issue, and more.
From the ‘scurfy’ mouse to the Nobel Prize: How a Seattle biotech pioneer’s long game paid off
STAT+: The latest biotech news: RevMed, Roche, Kyverna CAR-T therapy
Everything you need to know about biotech today from The Readout newsletter
Neuro Startup Tortugas Unveils $106M and a Pipeline of Drugs for the Brain
Tortugas Neurosciences’ two lead programs are in-licensed oral small molecules in development for schizophrenia and tinnitus. The startup is led …
STAT+: Kelonia Therapeutics’ road from floundering to $3 billion
BioAge bets on inflammation, a short Pfizer career, and more biotech news from The Readout
STAT+: Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride
Kelonia Therapeutics, a small biotech company, long struggled to stay afloat. Now it's been acquired by Eli Lilly for $3.25 …
You've seen all articles for #biotech.
Check back
soon
for new stories.